Current concepts in the management of uveitic macular edema

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Devising treatment strategies for uveitic macular edema (UME) is challenging because the UME can persist even when the uveitic inflammation has been controlled by immunosuppressive agents. Increasing systemic immunosuppressive treatment may not lead to improvement of edema, and adjunctive therapy, often with corticosteroids, is frequently needed. Published reports describe various agents for UME, but there is no consensus as to which treatments are preferred. A Medline search was performed for clinical studies of the treatment of UME, and the Web site www.clinicaltrials.gov was consulted to see if there were relevant clinical trials. This article highlights results from those searches. The evidence level is overall low (usually level 2 or 3) for the treatment of macular edema in uveitis. Most studies showed no more than slight benefit to treatment possibly because visual improvement was limited by damage from prior edema. A variety of corticosteroids and various routes of administration have been studied. More recently biologic agents and other immunomodulatory drugs have been employed. Improved study designs with randomization, sufficient sample size, and follow-up are necessary to define the optimal management of UME. Outcome measures of standardized visual acuity using Early Treatment Diabetic Retinopathy Study charts and optical coherence tomography parameters will provide additional information on structure and function beyond the standard assessment of fluo-rescein leakage.

Original languageEnglish
Pages (from-to)60-66
Number of pages7
JournalJohns Hopkins Advanced Studies in Ophthalmology
Volume7
Issue number2
StatePublished - Dec 1 2010

Fingerprint

Macular Edema
Immunosuppressive Agents
Edema
Adrenal Cortex Hormones
Uveitis
Optical Coherence Tomography
Biological Factors
Diabetic Retinopathy
Random Allocation
Sample Size
Visual Acuity
Consensus
Outcome Assessment (Health Care)
Clinical Trials
Inflammation
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Current concepts in the management of uveitic macular edema. / Davis, Janet L.

In: Johns Hopkins Advanced Studies in Ophthalmology, Vol. 7, No. 2, 01.12.2010, p. 60-66.

Research output: Contribution to journalArticle

@article{c5a7d352b2ce4853ae0b9a9beeedb6fd,
title = "Current concepts in the management of uveitic macular edema",
abstract = "Devising treatment strategies for uveitic macular edema (UME) is challenging because the UME can persist even when the uveitic inflammation has been controlled by immunosuppressive agents. Increasing systemic immunosuppressive treatment may not lead to improvement of edema, and adjunctive therapy, often with corticosteroids, is frequently needed. Published reports describe various agents for UME, but there is no consensus as to which treatments are preferred. A Medline search was performed for clinical studies of the treatment of UME, and the Web site www.clinicaltrials.gov was consulted to see if there were relevant clinical trials. This article highlights results from those searches. The evidence level is overall low (usually level 2 or 3) for the treatment of macular edema in uveitis. Most studies showed no more than slight benefit to treatment possibly because visual improvement was limited by damage from prior edema. A variety of corticosteroids and various routes of administration have been studied. More recently biologic agents and other immunomodulatory drugs have been employed. Improved study designs with randomization, sufficient sample size, and follow-up are necessary to define the optimal management of UME. Outcome measures of standardized visual acuity using Early Treatment Diabetic Retinopathy Study charts and optical coherence tomography parameters will provide additional information on structure and function beyond the standard assessment of fluo-rescein leakage.",
author = "Davis, {Janet L}",
year = "2010",
month = "12",
day = "1",
language = "English",
volume = "7",
pages = "60--66",
journal = "Johns Hopkins Advanced Studies in Ophthalmology",
issn = "1558-0202",
publisher = "Galen Publishing LLC",
number = "2",

}

TY - JOUR

T1 - Current concepts in the management of uveitic macular edema

AU - Davis, Janet L

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Devising treatment strategies for uveitic macular edema (UME) is challenging because the UME can persist even when the uveitic inflammation has been controlled by immunosuppressive agents. Increasing systemic immunosuppressive treatment may not lead to improvement of edema, and adjunctive therapy, often with corticosteroids, is frequently needed. Published reports describe various agents for UME, but there is no consensus as to which treatments are preferred. A Medline search was performed for clinical studies of the treatment of UME, and the Web site www.clinicaltrials.gov was consulted to see if there were relevant clinical trials. This article highlights results from those searches. The evidence level is overall low (usually level 2 or 3) for the treatment of macular edema in uveitis. Most studies showed no more than slight benefit to treatment possibly because visual improvement was limited by damage from prior edema. A variety of corticosteroids and various routes of administration have been studied. More recently biologic agents and other immunomodulatory drugs have been employed. Improved study designs with randomization, sufficient sample size, and follow-up are necessary to define the optimal management of UME. Outcome measures of standardized visual acuity using Early Treatment Diabetic Retinopathy Study charts and optical coherence tomography parameters will provide additional information on structure and function beyond the standard assessment of fluo-rescein leakage.

AB - Devising treatment strategies for uveitic macular edema (UME) is challenging because the UME can persist even when the uveitic inflammation has been controlled by immunosuppressive agents. Increasing systemic immunosuppressive treatment may not lead to improvement of edema, and adjunctive therapy, often with corticosteroids, is frequently needed. Published reports describe various agents for UME, but there is no consensus as to which treatments are preferred. A Medline search was performed for clinical studies of the treatment of UME, and the Web site www.clinicaltrials.gov was consulted to see if there were relevant clinical trials. This article highlights results from those searches. The evidence level is overall low (usually level 2 or 3) for the treatment of macular edema in uveitis. Most studies showed no more than slight benefit to treatment possibly because visual improvement was limited by damage from prior edema. A variety of corticosteroids and various routes of administration have been studied. More recently biologic agents and other immunomodulatory drugs have been employed. Improved study designs with randomization, sufficient sample size, and follow-up are necessary to define the optimal management of UME. Outcome measures of standardized visual acuity using Early Treatment Diabetic Retinopathy Study charts and optical coherence tomography parameters will provide additional information on structure and function beyond the standard assessment of fluo-rescein leakage.

UR - http://www.scopus.com/inward/record.url?scp=80052072488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052072488&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:80052072488

VL - 7

SP - 60

EP - 66

JO - Johns Hopkins Advanced Studies in Ophthalmology

JF - Johns Hopkins Advanced Studies in Ophthalmology

SN - 1558-0202

IS - 2

ER -